| Literature DB >> 35054850 |
Maryia Drobysh1,2, Almira Ramanaviciene2, Roman Viter3,4, Chien-Fu Chen5, Urte Samukaite-Bubniene1,2, Vilma Ratautaite1,2, Arunas Ramanavicius1,2.
Abstract
Monitoring and tracking infection is required in order to reduce the spread of the coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To achieve this goal, the development and deployment of quick, accurate, and sensitive diagnostic methods are necessary. The determination of the SARS-CoV-2 virus is performed by biosensing devices, which vary according to detection methods and the biomarkers which are inducing/providing an analytical signal. RNA hybridisation, antigen-antibody affinity interaction, and a variety of other biological reactions are commonly used to generate analytical signals that can be precisely detected using electrochemical, electrochemiluminescence, optical, and other methodologies and transducers. Electrochemical biosensors, in particular, correspond to the current trend of bioanalytical process acceleration and simplification. Immunosensors are based on the determination of antigen-antibody interaction, which on some occasions can be determined in a label-free mode with sufficient sensitivity.Entities:
Keywords: COVID-19; RNA analysis; SARS-CoV-2 virus; antigen-antibody interaction; bioelectrochemistry; biosensors; electrochemical immunosensors; immobilisation of biomolecules; immune complex; molecularly imprinted polymers (MIPs)
Mesh:
Year: 2022 PMID: 35054850 PMCID: PMC8776074 DOI: 10.3390/ijms23020666
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Location, mass, and function of SARS-CoV-2 structural proteins.
|
|
|
|
|
| S-protein | ∼180 kDa [ | Accession and infection of a host cell. | |
| E-protein | ∼10 kDa [ | Viral envelope formation. Assembly and development of the virus. | |
| N-protein | ∼45–60 kDa [ | Virion shaping. | |
| M-protein | ∼25–30 kDa [ | Formation of the viral envelope. |
Figure 1The strategies of COVID-19 diagnosis.
Figure 2The basic outline of electrochemical biosensors for detecting NA sequences.
Figure 3The schematic illustration of DNA tetrahedron formation by annealing of four ssDNA strains followed by the immobilisation DNA tetrahedron on the gold electrode surface.
Figure 4The general working concept of a split luciferase-based biosensor. Figure from [22].
Figure 5Schematic representation of FET immunosensor. Figure from [22].
Summary table of the reviewed biosensors.
| Biosensor | Biorecognition Element | Signal Source | Registration Methods | Label Need | LOD | Sensitivity | Test Time | Sample | Reference | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular tests | |||||||||||
| Electrochemical | Calixarene functionalised graphene-based | Capture NA | RNA hybrid. | DPV-signal | Label NA | 200 copies/mL | 85.5% | - | Clinical | [ | |
| RCA | Circular DNA template | Amplicons hybrid. | Redox dye | 1 copy/μL | - | ~2 h | Nasopharyngeal swabs | [ | |||
| Antisense oligonucleotides | ssDNA specific for N-gene | ssDNA-RNA hybrid. | Current-voltage signal conditioning circuit | Label-free | 6.9 copies/μL | 231 copies/μL | ~5 min | Nasal swab/saliva sample | [ | ||
| ECL | Capture NA specific for RdRp | RNA hybrid. | EIS and ECL | Luminescence label | 2.67 fM | - | - | Serum | [ | ||
| Plasmonic | Capture NA | PPT+LSPR | Label-free | 0.22 pM | - | - | Respiratory samples | [ | |||
| Serological tests | |||||||||||
| Antibodies against SARS-CoV-2 tests | Electrochemical | ePAD | S-protein containing RBD | Antibody-antigen affinity | SWV | Redox probe | 1 ng/mL | 100%, | ~30 min | Serum | [ |
| AJ-based | S1-protein and RBD | EIS | 2.8 fM (Ab against S1); | - | Within seconds | [ | |||||
| Spectroscopic ellipsometry | N-protein | TIRE+SPR signals | Label-free | - | - | - | [ | ||||
| Optical | S- or N-protein | Photoluminescence | SmBiT and | - | 89% (S-sensor); | - | [ | ||||
| Structural SARS-CoV-2 proteins or whole virus tests | Electrochemical | Electrode-tethered | Antibody against S-protein | Chronoamperometry | Redox probe | - | - | ~5 min | Saliva | [ | |
| VIC | CNT/WO3 modified electrode selective to VPs | VP binding | EIS | FCN/DCIP | 57 pg/mL | - | - | Nasopharyngeal swabs | [ | ||
| Cotton-tipped | Antibody against N-protein | Antibody-antigen affinity | SWV | Redox probe | 0.8 pg/mL | - | - | [ | |||
| fGO/GCE | Antibody against | Redox probe | 1 ag/mL | 93.3% | 5–35 min | Saliva/oropharyngeal swab | [ | ||||
| MIP-based | Selective to N-protein | Antigens- binding | DPV | Redox probe | 15 fM | - | - | Nasopharyngeal swabs | [ | ||
| Selective to S1-subunit | SWV | 15 fM | - | 15 min | - | [ | |||||
| Selective to S-RBD | EIS | 0.7 pg/mL | - | - | - | [ | |||||
| Selective to S-protein | CV, DPV, amperometry, EIS | Volt: 0.326 fg/mL | - | - | - | [ | |||||
| Selective to S-RBD | SPR | - | - | - | - | [ | |||||
| TiO2 nanotube-based | Co-TNTs | S-RBD oxidation | Amperometry | Label-free | 0.7 nM | - | ~30 s | Nasal secretions and saliva samples | [ | ||
| Cell-based | Antibody against S1-protein | Antibody-antigen affinity | BERA | 1 fg/mL | - | ~3 min | Saliva | [ | |||
| nPSR | Antibody against S-protein | SPR | 370 vp/mL | - | ~15 min (POC) | Nasopharyngeal swabs/Saliva | [ | ||||
| FET | Surface properties alterations | FET current response | 242 copies/mL | - | - | Nasopharyngeal swab | [ | ||||
| QCM | S-protein binding | Change of QCM resonance frequency | - | - | - | Oral swab samples | [ | ||||
| Other tests | |||||||||||
| ROS detection | MWCNT | ROS level | CV | Label-free | Sputum sample vol. < 500 μL | >97% | ~30 s | Sputum | [ | ||
| Multiplexed nanomaterial-based | Organic ligands | COVID-19 related VOCs | Electrical/electrochemical | - | - | - | Exhaled breath | [ | |||